Banque Cantonale Vaudoise Boosts Stake in Hologic, Inc. (NASDAQ:HOLX)

Banque Cantonale Vaudoise raised its position in Hologic, Inc. (NASDAQ:HOLX) by 9.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,153 shares of the medical equipment provider’s stock after buying an additional 3,064 shares during the period. Banque Cantonale Vaudoise’s holdings in Hologic were worth $2,610,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new stake in Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the 1st quarter worth approximately $37,000. Mather Group LLC. purchased a new stake in shares of Hologic during the 1st quarter worth approximately $48,000. Massmutual Trust Co. FSB ADV increased its stake in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares during the last quarter. Finally, Toth Financial Advisory Corp increased its stake in shares of Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hologic Price Performance

NASDAQ:HOLX traded up $0.48 during trading hours on Friday, hitting $81.24. The stock had a trading volume of 1,206,444 shares, compared to its average volume of 1,633,144. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29. The firm has a market capitalization of $18.96 billion, a price-to-earnings ratio of 41.45, a P/E/G ratio of 2.64 and a beta of 0.99. The company has a 50 day simple moving average of $78.59 and a two-hundred day simple moving average of $76.35. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the company earned $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on HOLX shares. JPMorgan Chase & Co. raised their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. Argus lifted their price objective on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, Stephens reiterated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.